2024-518440-20-00招募中1 期
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of T7-010 in Healthy Participants.
T7 Therapeutics Inc.1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2025年5月27日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Caroline Fortier
Scientific
T7 Therapeutics Inc.
研究点 (1)
Loading locations...
相似试验
终止
1 期
A study to evaluate safety and tolerability of GS -5801 in healthy subjectsHepatitis B VirusInfection - Other infectious diseasesOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12616001260415Gilead Sciences, Inc.70
撤回
1 期
A Study of ELVN-002 in Healthy Adult Volunteers: Part BNon-small Cell lung canceron-small Cell lung cancerCancer - Lung - Non small cellACTRN12623000431628Enliven Therapeutics, Inc.6
撤回
不适用
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Injection of ABT-110 in Healthy Volunteers and Subjects with Chronic Low Back Paichronic low back pain10028302NL-OMON36923Abbott30
已完成
1 期
A phase 1 clinical trial of BIL06v/Alhydrogel to evaluate the safety, tolerability, immunogenicity and anti-tumour activity and to determine the most effective dose of BIL06v/Alhydrogel to treat patients with advanced forms of solid cancersAdvanced Solid CancersCancer - Any cancerACTRN12618000838213Biosceptre (Aust) Pty Limited29
尚未招募
不适用
A Phase 1 Study to Evaluate the Safety, Tolerability and Efficacy of MK-8353 Combination Therapies in Subjects With Advanced Solid Tumorsadvanced solid tumor10017991NL-OMON37039Merck Sharp & Dohme (MSD)24